Inhaled corticosteroid and long-acting β2-agonist pharmacological profiles: effective asthma therapy in practice

Ankerst, 2005, Combination inhalers containing inhaled corticosteroids and long-acting beta2-agonists: improved clinical efficacy and dosing options in patients with asthma, J Asthma, 42, 715, 10.1080/02770900500305748

Pauwels, 1997, Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group, N Engl J Med, 337, 1405, 10.1056/NEJM199711133372001

Woolcock, 1996, Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids, Am J Respir Crit Care Med, 153, 1481, 10.1164/ajrccm.153.5.8630590

Greening, 1994, Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group, Lancet, 344, 219, 10.1016/S0140-6736(94)92996-3

Langmack, 2010, Heterogeneity of response to asthma controller therapy: clinical implications, Curr Opin Pulm Med, 16, 13, 10.1097/MCP.0b013e328333af9c

Lazarus, 2001, Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial, JAMA, 285, 2583, 10.1001/jama.285.20.2583

Nelson, 2010, Safety of formoterol in patients with asthma: combined analysis of data from double-blind, randomized controlled trials, J Allergy Clin Immunol, 125, 390, 10.1016/j.jaci.2009.11.036

Price, 2003, Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma, Thorax, 58, 211, 10.1136/thorax.58.3.211

Vaquerizo, 2003, Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma, Thorax, 58, 204, 10.1136/thorax.58.3.204

Price, 2011, Leukotriene antagonists as first-line or add-on asthma-controller therapy, N Engl J Med, 364, 1695, 10.1056/NEJMoa1010846

Dahlén, 2011, Asthma treatment guidelines meet the real world, N Engl J Med, 364, 1769, 10.1056/NEJMe1100937

Nelson, 2000, Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast, J Allergy Clin Immunol, 106, 1088, 10.1067/mai.2000.110920

Fish, 2001, Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy, Chest, 120, 423, 10.1378/chest.120.2.423

Ducharme, 2006, Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma, Cochrane Database Syst Rev, CD003137

Ringdal, 2003, The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma, Respir Med, 97, 234, 10.1053/rmed.2003.1436

Peters, 2010, Tiotropium bromide step-up therapy for adults with uncontrolled asthma, N Engl J Med, 363, 1715, 10.1056/NEJMoa1008770

Kerstjens, 2012, Tiotropium in asthma poorly controlled with standard combination therapy, N Engl J Med, 367, 1198, 10.1056/NEJMoa1208606

Huchon, 2009, Lung function and asthma control with beclomethasone and formoterol in a single inhaler, Respir Med, 103, 41, 10.1016/j.rmed.2008.09.002

Nelson, 2003, Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers, J Allergy Clin Immunol, 112, 29, 10.1067/mai.2003.1558

Marceau, 2006, Persistence, adherence, and effectiveness of combination therapy among adult patients with asthma, J Allergy Clin Immunol, 118, 574, 10.1016/j.jaci.2006.06.034

Murphy, 2009, Treatment of moderate to severe asthma: patient perspectives on combination inhaler therapy and implications for adherence, J Asthma Allergy, 2, 63, 10.2147/JAA.S4214

Stoloff, 2004, Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies, J Allergy Clin Immunol, 113, 245, 10.1016/j.jaci.2003.10.011

Stempel, 2005, Adherence to asthma controller medication regimens, Respir Med, 99, 1263, 10.1016/j.rmed.2005.03.002

Lasserson, 2010, Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children, Cochrane Database Syst Rev, CD004106

Papi, 2007, Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma, Allergy, 62, 1182, 10.1111/j.1398-9995.2007.01493.x

Papi, 2007, Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma, Eur Respir J, 29, 682, 10.1183/09031936.00095906

Shepherd, 2008, Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over, Health Technol Assess, 12, 1, 10.3310/hta12190

Rohatagi, 2004, Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective, J Clin Pharmacol, 44, 37, 10.1177/0091270003260334

van Noord, 1996, Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action, Eur Respir J, 9, 1684, 10.1183/09031936.96.09081684

Palmqvist, 1997, Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency, Eur Respir J, 10, 2484, 10.1183/09031936.97.10112489

Giembycz, 2006, Beyond the dogma: novel beta2-adrenoceptor signalling in the airways, Eur Respir J, 27, 1286, 10.1183/09031936.06.00112605

Collins, 1988, Beta-adrenergic receptors in hamster smooth muscle cells are transcriptionally regulated by glucocorticoids, J Biol Chem, 263, 9067, 10.1016/S0021-9258(19)76507-7

Mak, 1995, Glucocorticosteroids increase beta 2-adrenergic receptor transcription in human lung, Am J Physiol, 268, L41

Adcock, 1996, Interactions of glucocorticoids and beta 2-agonists, Eur Respir J, 9, 160, 10.1183/09031936.96.09010160

Baraniuk, 1997, Glucocorticoids induce beta2-adrenergic receptor function in human nasal mucosa, Am J Respir Crit Care Med, 155, 704, 10.1164/ajrccm.155.2.9032216

Cheung, 1992, Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyper-responsiveness in patients with mild asthma, N Engl J Med, 327, 1198, 10.1056/NEJM199210223271703

Mak, 1995, Protective effects of a glucocorticoid on downregulation of pulmonary beta 2-adrenergic receptors in vivo, J Clin Invest, 96, 99, 10.1172/JCI118084

Kalavantavanich, 2000, Dexamethasone potentiates high-affinity beta-agonist binding and g(s)alpha protein expression in airway smooth muscle, Am J Physiol Lung Cell Mol Physiol, 278, L1101, 10.1152/ajplung.2000.278.5.L1101

Horvath, 2007, The effect of corticosteroids on the disposal of long-acting beta2-agonists by airway smooth muscle cells, J Allergy Clin Immunol, 120, 1103, 10.1016/j.jaci.2007.08.034

Usmani, 2005, Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy, Am J Respir Crit Care Med, 172, 704, 10.1164/rccm.200408-1041OC

Roth, 2002, Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling, Lancet, 360, 1293, 10.1016/S0140-6736(02)11319-5

Kaur, 2008, Long-acting beta2-adrenoceptor agonists synergistically enhance glucocorticoid-dependent transcription in human airway epithelial and smooth muscle cells, Mol Pharmacol, 73, 203, 10.1124/mol.107.040121

Loven, 2007, Anti-inflammatory activity of beta2-agonists in primary lung epithelial cells is independent of glucocorticoid receptor, Eur Respir J, 30, 848, 10.1183/09031936.00129606

Barnes, 2002, Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids, Eur Respir J, 19, 182, 10.1183/09031936.02.00283202

Sindi, 2009, Antiinflammatory effects of long-acting beta2-agonists in patients with asthma: a systematic review and metaanalysis, Chest, 136, 145, 10.1378/chest.08-2149

Postma, 2008, Inhaled corticosteroids and long-acting beta-agonists in adult asthma: a winning combination in all?, Naunyn Schmiedebergs Arch Pharmacol, 378, 203, 10.1007/s00210-008-0302-y

An, 2007, Airway smooth muscle dynamics: a common pathway of airway obstruction in asthma, Eur Respir J, 29, 834, 10.1183/09031936.00112606

Borger, 2009, Impaired translation of CCAAT/enhancer binding protein alpha mRNA in bronchial smooth muscle cells of asthmatic patients, J Allergy Clin Immunol, 123, 45, 10.1016/j.jaci.2008.11.006

Roth, 2004, Dysfunctional interaction of C/EBPalpha and the glucocorticoid receptor in asthmatic bronchial smooth-muscle cells, N Engl J Med, 351, 560, 10.1056/NEJMoa021660

Roth, 2012, Formoterol reduces asthmatic airway smooth muscle cell proliferation through p27 (Kip) which is supported by steroids, Eur Respir J, 40

Roth, 2012, Formoterol and fluticasone reduce the deposition of pro-inflammatory collagens, Eur Respir J, 40

Giembycz, 2008, A Holy Grail of asthma management: toward understanding how long-acting β2-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids, Br J Pharmacol, 153, 1090, 10.1038/sj.bjp.0707627

Chakir, 2003, Airway remodeling-associated mediators in moderate to severe asthma: Effect of steroids on TGF-β, IL-11, IL-17, and type I and type III collagen expression, J Allergy Clin Immunol, 111, 1293, 10.1067/mai.2003.1557

Theophilus, 2006, Co-deposition of salmeterol and fluticasone propionate by a combination inhaler, Int J Pharm, 313, 14, 10.1016/j.ijpharm.2006.01.018

Barnes, 2005, Histone acetylation and deacetylation: importance in inflammatory lung diseases, Eur Respir J, 25, 552, 10.1183/09031936.05.00117504

Umland, 2002, Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma, Pulm Pharmacol Ther, 15, 35, 10.1006/pupt.2001.0312

Kelly, 2009, Comparison of inhaled corticosteroids: an update, Ann Pharmacother, 43, 519, 10.1345/aph.1L546

Derendorf, 2006, Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma, Eur Respir J, 28, 1042, 10.1183/09031936.00074905

Derendorf, 2007, Pharmacokinetic and pharmacodynamic properties of inhaled ciclesonide, J Clin Pharmacol, 47, 782, 10.1177/0091270007299763

Derendorf, 2002, Bioavailability and metabolism of mometasone furoate: pharmacology versus methodology, J Clin Pharmacol, 42, 383, 10.1177/0091270002424003

Hubner, 2005, Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids, Immunol Allergy Clin North Am, 25, 469, 10.1016/j.iac.2005.05.004

Johnson, 1998, Development of fluticasone propionate and comparison with other inhaled corticosteroids, J Allergy Clin Immunol, 101, S434, 10.1016/S0091-6749(98)70155-1

Yzet, 2010, Dynamic measurements of total hepatic blood flow with Phase Contrast MRI, Eur J Radiol, 73, 119, 10.1016/j.ejrad.2008.09.032

Phillipps, 1990, Structure-activity relationships of topically active steroids: the selection of fluticasone propionate, Respir Med, 84, 19, 10.1016/S0954-6111(08)80003-0

Grove, 1995, Expression of the beta 2 adrenoceptor partial agonist/antagonist activity of salbutamol in states of low and high adrenergic tone, Thorax, 50, 134, 10.1136/thx.50.2.134

Palmqvist, 1999, Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients, Am J Respir Crit Care Med, 160, 244, 10.1164/ajrccm.160.1.9901063

Politiek, 1999, Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction, Eur Respir J, 13, 988, 10.1034/j.1399-3003.1999.13e10.x

van Noord, 1998, A comparison of the onset of action of salbutamol and formoterol in reversing methacholine-induced bronchoconstriction, Respir Med, 92, 1348, 10.1016/S0954-6111(98)90140-8

Beach, 1996, Speeds of action of single doses of formoterol and salbutamol compared with placebo in reversing methacholine-induced bronchoconstriction, Pulm Pharmacol, 9, 245, 10.1006/pulp.1996.0031

Foradil

Johnson, 2006, Molecular mechanisms of β2-adrenergic receptor function, response, and regulation, J Allergy Clin Immunol, 117, 18, 10.1016/j.jaci.2005.11.012

Coleman, 1996, Exosites: their current status, and their relevance to the duration of action of long-acting beta2-adrenoceptor agonists, Trends Pharmacol Sci, 17, 324, 10.1016/0165-6147(96)10040-7

Lotvall, 2008, Long duration of airway but not systemic effects of inhaled formoterol in asthmatic patients, Respir Med, 102, 449, 10.1016/j.rmed.2007.10.003

Lotvall, 2006, Inhaled steroid/long-acting β2 agonist combination products provide 24 hours improvement in lung function in adult asthmatic patients, Respir Res, 7, 110, 10.1186/1465-9921-7-110

Masoli, 2006, The 24 h duration of bronchodilator action of the budesonide/formoterol combination inhaler, Respir Med, 100, 20, 10.1016/j.rmed.2005.04.012

Cazzola, 2012, Pharmacology and therapeutics of bronchodilators, Pharmacol Rev, 64, 450, 10.1124/pr.111.004580

Cazzola, 2011, β(2)-adrenoceptor agonists: current and future direction, Br J Pharmacol, 163, 4, 10.1111/j.1476-5381.2011.01216.x

Sturton, 2008, Pharmacological characterization of indacaterol, a novel once daily inhaled β2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices, J Pharmacol Exp Ther, 324, 270, 10.1124/jpet.107.129296

Lombardi, 2009, Lipid membrane interactions of indacaterol and salmeterol: Do they influence their pharmacological properties?, Eur J Pharm Sci, 38, 533, 10.1016/j.ejps.2009.10.001

Frois, 2009, Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol, Clin Ther, 31, 2779, 10.1016/j.clinthera.2009.12.021

Jaeschke, 2008, The safety of long-acting beta-agonists among patients with asthma using inhaled corticosteroids: systematic review and metaanalysis, Am J Respir Crit Care Med, 178, 1009, 10.1164/rccm.200804-494OC

Dissanayake, 2012, Fluticasone/formoterol: a new single-aerosol combination therapy for patients with asthma, Respir Med, 106, S20, 10.1016/S0954-6111(12)70006-9

Pritchard, 2001, The influence of lung deposition on clinical response, J Aerosol Med, 14, S19, 10.1089/08942680150506303

Usmani, 2003, Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols, J Appl Physiol, 95, 2106, 10.1152/japplphysiol.00525.2003

Newman, 2008, In vitro/in vivo comparisons in pulmonary drug delivery, J Aerosol Med Pulm Drug Deliv, 21, 77, 10.1089/jamp.2007.0643

Mitchell, 2004, Particle size analysis of aerosols from medicinal inhalers, KONA, 22, 32, 10.14356/kona.2004010

Martin, 2002, Therapeutic significance of distal airway inflammation in asthma, J Allergy Clin Immunol, 109, S447, 10.1067/mai.2002.121409

Burgel, 2009, Update on the roles of distal airways in asthma, Eur Respir Rev, 18, 80, 10.1183/09059180.00001109

Taylor, 2005, Do all dry powder inhalers show the same pharmaceutical performance?, Int J Clin Pract, 59, 7, 10.1111/j.1368-504X.2005.00721.x

Chrystyn, 2009, Not all asthma inhalers are the same: factors to consider when prescribing an inhaler, Prim Care Respir J, 18, 243, 10.4104/pcrj.2009.00029

Chrystyn, 2007, The Diskus(tm): a review of its position among dry powder inhaler devices, Int J Clin Pract, 61, 1022, 10.1111/j.1742-1241.2007.01382.x

Lewis, 2005, Modulite: a simple solution to a difficult problem, Respiration, 72, 3, 10.1159/000083686

Colice, 2000, Comparing inhaled corticosteroids, Respir Care, 45, 846

Luijk, 2004, Duration of effect of single-dose inhaled fluticasone propionate on AMP-induced bronchoconstriction, Eur Respir J, 23, 559, 10.1183/09031936.04.00043504